Coscia et al.45showed that CT45 regulated the sensitivity of ovarian cancer to chemotherapy by affecting the DNA damage repair pathway and may improve the response of patients to immunotargeted therapy; they also found that CT45 is an inherent chemotherapeutic sensitivity enhancer of cells and a nonmutational tumor antigen recognized by cytotoxic T cells. Here, CT45A1 is linked to ovarian carcinoma.